US9724296B2 - Chewable gelled emulsions - Google Patents

Chewable gelled emulsions Download PDF

Info

Publication number
US9724296B2
US9724296B2 US14/515,297 US201414515297A US9724296B2 US 9724296 B2 US9724296 B2 US 9724296B2 US 201414515297 A US201414515297 A US 201414515297A US 9724296 B2 US9724296 B2 US 9724296B2
Authority
US
United States
Prior art keywords
hydrochloride
oil
emulsion
dose
aqueous phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US14/515,297
Other versions
US20150037438A1 (en
Inventor
Tore Seternes
Kurt Ingar Draget
Ingvild Johanne Haug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitux Group As
Original Assignee
Vitux Group As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/515,297 priority Critical patent/US9724296B2/en
Application filed by Vitux Group As filed Critical Vitux Group As
Publication of US20150037438A1 publication Critical patent/US20150037438A1/en
Assigned to AYANDA AS reassignment AYANDA AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DRAGET, KURT INGAR, HAUG, INGVILD JOHANNE, SETERNES, TORE
Assigned to AYANDA GROUP AS reassignment AYANDA GROUP AS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PROBIO ASA
Assigned to AYANDA GROUP AS reassignment AYANDA GROUP AS CHANGE OF ADDRESS Assignors: AYANDA GROUP AS
Assigned to PROBIO ASA reassignment PROBIO ASA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AYANDA AS
Assigned to AYANDA GROUP AS reassignment AYANDA GROUP AS CHANGE OF ADDRESS Assignors: AYANDA GROUP AS
Assigned to VITUX GROUP AS reassignment VITUX GROUP AS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AYANDA GROUP AS
Priority to US15/639,047 priority patent/US10668013B2/en
Publication of US9724296B2 publication Critical patent/US9724296B2/en
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to oral pharmaceutical compositions comprising a soft, gelled oil-in-water emulsion containing a drug substance, preferably a lipophilic drug substance, but optionally a hydrophilic or amphiphilic drug substance, to processes for their preparation, and to their use.
  • a drug substance preferably a lipophilic drug substance, but optionally a hydrophilic or amphiphilic drug substance
  • the oral unit dosage forms e.g. tablets or capsules
  • the oral unit dosage forms may likewise be large and so difficult for elderly or young patients to swallow and moreover may cause a gagging reaction even with healthy adults.
  • any therapeutic or prophylactic dosage regime which involves the consumption of large numbers of dose units or numbers of large, difficult to swallow, dose units is inherently at risk of patient non-compliance.
  • lipophilic drug substances may be administered without these problems when contained within a piece of soft, chewable, gelled oil-in-water emulsion.
  • lipophilic compounds are increased by providing such compounds in the form of a soft, gelled oil-in-water emulsion.
  • each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.
  • the invention provides a process for preparing an oral pharmaceutical composition in unit dose form, which process comprises: forming an oil phase comprising a lipophilic drug substance dissolved or dispersed in a physiologically tolerable oil such as one comprising a polyunsaturated fatty acid ester, e.g.
  • an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil preferably an omega-3 acid ester, particularly an EPA ester, a docosahexaenoic acid (DHA) ester or a combination of EPA and DHA esters; forming an aqueous phase comprising an aqueous solution of a physiologically tolerable gelling agent; forming an oil-in-water emulsion with said oil phase and said aqueous phase, allowing said emulsion to gel to form a soft chewable mass; and, before, during or after gelling of said emulsion, dividing said emulsion into dose units.
  • an omega-3 acid ester preferably an omega-3 acid ester, particularly an EPA ester, a docosahexaenoic acid (DHA) ester or a combination of EPA and DHA esters
  • forming an aqueous phase comprising an aqueous solution of a physiologically tolerable gelling agent
  • the invention provides an oral pharmaceutical composition in unit dose form, each unit dose comprising a hydrophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled water-in-oil-in-water double emulsion.
  • a water-in-oil emulsion comprising the water soluble drug substance in the aqueous phase is further emulsified with an aqueous phase comprising an aqueous solution of a physiologically tolerable gelling agent. This is especially useful when the hydrophilic drug substances to be administrated have a strong, unpleasant taste.
  • the invention provides a process for preparing an oral pharmaceutical composition in unit dose form, which process comprises: forming an oil phase comprising a physiologically tolerable oil such as one comprising a polyunsaturated fatty acid ester, e.g.
  • an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil preferably an omega-3 acid ester, particularly an EPA ester, a docosahexaenoic acid (DHA) ester or a combination of EPA and DHA esters; forming an aqueous phase comprising an aqueous solution of a hydrophilic drug substance dissolved or dispersed therein; forming a water-in-oil emulsion with said oil phase and said aqueous phase, forming an oil-in-water emulsion with said water-in-oil phase and a further aqueous phase, comprising an aqueous solution of a physiologically tolerable gelling agent, allowing said emulsion to gel to form a soft chewable mass; and, before, during or after gelling of said emulsion, dividing said emulsion into dose units.
  • an omega-3 acid ester preferably an omega-3 acid ester, particularly an EPA ester, a
  • the soft, gelled dose units of the present invention can remain intact during passage through the stomach and release the drug substances disposed within the gel matrix further down the gastrointestinal tract where the environment is not so harsh and where uptake is feasible. In this format some of the drug substance at the periphery of the matrix may be degraded by gastric fluid during stomach transit. Nonetheless, the soft, gelled dose units of the present invention have the advantage of being chewable and so more easily swallowed if large, e.g. above 1000 mg, more especially 1500 to 5000 mg. In the case where a large dose is required, the advantage of a single chewable dose unit may outweigh the relatively small loss of drug substance from the periphery of the chewed fragments during stomach transit. Chewable gel units moreover have the advantage that patient compliance is greater for patients with a gag reaction to swallowing tablets or capsules intact, in particular juvenile or elderly patients.
  • each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion capable of remaining substantially intact during passage through the stomach.
  • each unit dose comprising a hydrophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled water-in-oil-in-water double emulsion capable of remaining substantially intact during passage through the stomach.
  • soft and chewable it is meant that the gelled emulsion is readily deformable rather than rigid while yet being self supporting, i.e. that it will not flow like a viscous liquid, and that it may be readily fragmented upon chewing, i.e. so that it need not be swallowed whole.
  • a gelled emulsion may be compressed, at least substantially reversibly, i.e. elastically, by at least 10%, preferably at least 40% upon application of a force/deformation gradient of 0.1 mm/s at 21° C., 50% relative humidity and atmospheric pressure.
  • the compression breaking strengths of the soft, gelled dose units of the present invention are greater than 500 g/cm 2 , particularly greater than 1000 g/cm 2 , especially preferably greater than 2000 g/cm 2 , e.g. 2900-3600 g/cm 2 .
  • each dose unit contains one piece of gelled emulsion. Such pieces may be referred to hereinafter as “cores”.
  • the cores may be formed from larger pieces of gelled emulsion, e.g. by cutting, or, more preferably by extrusion or molding of dose units of incompletely gelled emulsion.
  • drug substance is meant a substance having a desirable therapeutic or prophylactic effect other than as a nutrient, i.e. substances of the type for which regulatory approval as a drug is required in for example the US or the European Union.
  • the drug substance may be a vitamin which classifies as a drug substance for regulatory purposes, e.g. vitamin A, K or D (e.g. ergocalciferol, alphacalcidol and calcitriol).
  • Vitamins, including these, as well as mineral and/or herbs may of course be included in the compositions in addition to non-vitamin drug substances.
  • amphiphilic drug substance is meant a drug substance that will distribute at the oil droplet surface.
  • the amphiphilic drug substance is mixed with the oil phase and in the double emulsion of the present invention the amphiphilic drug substance is mixed either with the oil or with the discontinuous aqueous phase of the double emulsion.
  • Examples of categories of suitable drug substances for use according to the invention include: analgesics; anti-inflammatories; anticancer agents; cardiovascular agents; biological agents; antiallergy agents (e.g. antihistamines); decongestants; antinausea agents, drugs affecting gastrointestinal function, drugs acting on the blood and blood-forming organs, drugs affecting renal and cardiovascular function, antifungal agents, urological agents, hormones, antimicrobial agents, antiepileptical agents, psycholeptical agents, antipsychotic agents, psychoanaleptical agents, anticholinesterase agents, drugs acting on the respiration organs and drugs acting on the eye.
  • hydrophilic drug substances for use according to the invention include: sodium acetazolamide, acetyl salicylic acid, aminophylline, amiodarone hydrochloride, ascorbic acid, atenolol, bendroflumethiazide, calcium folinate, captopril, cetrizine hydrochloride, chloramphenicol sodium succinate, chlorpheniramine maleate, chlorpromazine hydrochloride, cimetidine hydrochloride, ciprofloxacin hydrochloride, clindamycin hydrochloride, clonidine hydrochloride, codeine phosphate, cyclizine hydrochloride, cyclophosphamide, sodium dexamethasone phosphate, sodium dicloxacillin, dicyclomide hydrochloride, diltiazem hydrochloride, diphenhydramine hydrochloride, disopyramide phosphate, doxepin hydrochloride, enalapril
  • the quantity of drug substance per unit dose of the compositions of the invention will conveniently be in the range of 50 to 200%, especially 80 to 120%, of the quantity per unit dose in conventional formulations of the drug substance or 25, 50 or 100% of the normal recommended daily adult or child dose.
  • the quantity per unit dose is preferably 100 to 1500 mg, especially 200 to 1200 mg, particularly 400 to 600 mg.
  • compositions of the invention especially preferably consist of cores of gelled emulsion.
  • they may comprise a gelled emulsion core provided with a coating of a physiologically tolerable coating material.
  • Such coatings may be of the type conventional within the pharmaceutical industry and may be applied by conventional means, e.g. spraying or dipping.
  • a thin sugar (or otherwise sweetened) coating may be desired.
  • rigid coatings are generally not desired since it is central to the invention that the soft gelled core be chewable so as to facilitate swallowing.
  • the cores be non-spherical as this facilitates chewing. While disc and lenticular forms are suitable, it is preferred that the cores be elongate, for example having cylindrical or similar form (optionally of course with rounded ends and one or more planar side faces). Where the application is paediatric, the cores may be in child-attractive forms, e.g. in a geometric shape or in the shape of an animal or cartoon character. In this way, the unit dose may be consumed with ease by patients who otherwise might have difficulty swallowing a conventional tablet or capsule, e.g. the young, the old, those with gag reactions, patients on chemotherapy, and others with reduced mouth function.
  • the cores will generally be quite large, e.g. having a mass of 100 to 3000 mg, especially 400 to 2000 mg, particularly 600 to 1500 mg.
  • the cores may be smaller, e.g. as low as 50 mg, however even then larger cores may be used and in this event the compositions may be used as a source of beneficial oils, for example polyunsaturated fatty acid esters such as phospholipids, glycerides and lower alkyl (e.g. C 1-6 alkyl, especially ethyl) esters.
  • Preferred polyunsaturated acids in this regard include the omega-3 acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • the oil of the oil phase in the compositions of the invention may be any physiologically tolerable oil, such as one comprising a polyunsaturated fatty acid ester, e.g. an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil, preferably an omega-3 acid ester, but will preferably be one or a mixture of fatty acid esters (for example phospholipids, mono-, di- or tri-glycerides, and lower alkyl esters). Such materials may be natural, synthetic or semi-synthetic.
  • plant and marine oils e.g.
  • oils from plant seeds, algae, fish (especially oily fish), microorgansims and marine invertebrates (especially krill)) is especially preferred as is the use of DHA and/or EPA ethyl esters. Mammalian oils will generally be undesired.
  • the oil of the oil phase may be a 90% mixture of ethyl EPA ester and ethyl DPA ester. This is available as Omacor® from Pronova Biocare AS, Lysaker, Norway.
  • oils which are or majoritatively are polyunsaturated fatty acid esters may be desirable, especially where such esters contribute to the beneficial effect of the drug, for example where the drug substance is a cardiovascular therapy or anticancer therapy agent.
  • the oil phase will constitute 0.05 to 5 g, preferably 0.1 to 3 g, especially 0.2 to 2 g, particularly 0.3 to 1.25 g, more particularly 0.4 to 0.75 g, per dose unit.
  • the oil phase preferably constitutes 5 to 75% wt., especially at least 35 to 50% wt., e.g. 40 to 50% wt. of the dose unit.
  • the gelling agent used in the aqueous phase of the emulsion may be any physiologically tolerable gelling agent (preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein) or combination capable of forming a soft, chewable, self-supporting gelled oil-in-water emulsion.
  • physiologically tolerable gelling agent preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein) or combination capable of forming a soft, chewable, self-supporting gelled oil-in-water emulsion.
  • a saccharide e.g. an oligosaccharide or polysaccharide
  • protein or a glycoprotein e.g.
  • Preferred gelling agents include gelatins, alginates and carrageenans.
  • the use of gelatins is especially preferred as breakdown in the throat of trapped fragments is ensured and as cores having the desired properties may readily be produced using gelatins.
  • the gelled emulsion should be self-supporting, soft and fragmentable on chewing. It is not desired that the gelled emulsion should dissolve rapidly in the mouth without chewing as the administration of the composition would then differ little functionally from administration of an oil solution of the drug. Gelatin can be used to give the gelled emulsions these desired characteristics.
  • gelatins used as gelling agents in the composition of the invention may be produced from the collagen of any mammal or the collagen of any aquatic species, however the use of gelatin from salt-water fish and in particular cold and warm water fishes is preferred.
  • Gelatins having an imino acid content of 5 to 25% wt. are preferred, more especially those having an imino acid content of 10 to 25% wt.
  • the gelatins will typically have a weight average molecular weight in the range 10 to 250 kDa, preferably 75 to 220 kDa, especially 80 to 200 kDa.
  • Gelatins having no Bloom value or low Bloom values of 60-300, especially 90-200 are preferred. Where a gelatin of no Bloom value, e.g. a cold water fish gelatin, is used, this will typically be used together with another gelatin or other gelling agent. The combination of cold water and warm water fish gelatins is especially preferred.
  • the gelatin will typically be present in the aqueous phase at a concentration of 1 to 50% wt., preferably 2 to 35% wt., particularly 5 to 25% wt.
  • the weight ratio of gelatin to polysaccharide in the aqueous phase will typically be 50:1 to 5:1, preferably 40:1 to 9:1, especially 20:1 to 10:1.
  • polysaccharides or mixtures of polysaccharides and gelatin are used as the gelling agent
  • natural polysaccharides synthetic polysaccharides or semisynthetic polysaccharides, e.g. polysaccharides from plants, fish, terrestrial mammals, algae, bacteria and derivatives and fragmentation products thereof.
  • Typical marine polysaccharides include carageenans, alginates, agars and chitosans.
  • Typical plant polysaccharides include pectins.
  • Typical microorganism polysaccharides include gellans and scleroglucans. The use of charged, e.g.
  • electrostatically charged and/or sulfated polysaccharides is preferred, as is the use of marine polysaccharides, in particular carageenans, and alginates, especially carageenans.
  • Carageenans are used below as representative polysaccharide gelling agents.
  • the carageenan family which includes iota- and kappa-carageenans, is a family of linear sulfated polysaccharides produced from red algae.
  • the repeating disaccharide unit in kappa-carrageenan is ⁇ -D-galactose-4-sulfate and 3,6-anhydro- ⁇ -D-galactose, while that in iota-carrageenan is ⁇ -D-galactose-4-sulfate and 3,6-anhydro- ⁇ -D-galactose-2-sulfate.
  • Both kappa- and iota-carrageenans are used in food preparations.
  • the carrageenans are used as stabilisers, emulsifiers, gelling agents and fat replacers.
  • Both iota and kappa carrageenans form salt- or cold-setting reversible gels in an aqueous environment. Coil-helix transition and aggregation of helices form the gel network. Kappa-carrageenan has binding sites for specific monovalent cations, resulting in gel formation with decreasing shear and elastic moduli in the order Cs + >K + >>Na + >Li + . As a rule, an increasing salt concentration enhances the elastic modulus and the setting and melting temperatures of a kappa-carrageenan gel.
  • water-soluble potassium, rubidium, or caesium compounds, particularly potassium compounds, and particularly naturally occurring compounds e.g.
  • salts is preferred when kappa-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM, more especially up to 50 mM.
  • a salt-dependent conformational transition is also found for iota-carrageenan.
  • the molecules are also known to undergo coil-helix transition with strong helix-stabilisation in the presence of multivalent cations, like Ca 2+ .
  • the use of water-soluble calcium, strontium, barium, iron or aluminium compounds, especially calcium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when iota-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM.
  • the polysaccharide gelling agents used according to the invention will typically have weight average molecular weights of 5 kDa to 2 MDa, preferably 10 kDa to 1 MDa, most preferably 100 kDa to 900 kDa, particularly 200 to 800 kDa. They will typically be used at concentrations of 0.01 to 5% wt, preferably 0.1 to 1.5% wt., particularly 0.2 to 1% wt in the aqueous phase. Where mono or multivalent cations, typically group 1 or group 2 metal ions, are included in the aqueous phase, this will typically be at concentrations in the range 2.5 to 100 mM, particularly 5 to 50 mM.
  • emulsifiers emulsion stabilizers
  • pH modifiers emulsion modifiers
  • viscosity modifiers sweeteners
  • sweeteners fillers
  • vitamins e.g. vitamin C, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, folacin, panthotenic acid
  • minerals e.g., a lipophilic antioxidant, e.g. vitamin E
  • vitamins which may be present in the oil phase are vitamin A, vitamin D and vitamin K.
  • Such further components are used widely in the food, pharmaceutical and nutraceutical industries.
  • cellulose derivatives e.g. hydroxy methyl propyl cellulose
  • emulsion stabilizers is especially preferred.
  • the pH of the aqueous phase of the emulsion is preferably in the range 2 to 9, particularly 3 to 7.5.
  • the aqueous phase preferably has a gelling temperature in the range 10 to 30° C., more preferably 15 to 28° C., and a melting temperature in the range 20 to 80° C., more preferably 24 to 60° C., especially 28 to 50° C.
  • a sweetener is included in the aqueous phase, this will typically be selected from natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol and artificial sweeteners such as aspartame, acesulfame-K, neotame, saccharine, sucralose.
  • natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol
  • artificial sweeteners such as aspartame, acesulfam
  • the drug substance is an analgesic, especially paracetamol or acetylsalicylic acid, or an antihistamine
  • gelatin it is preferred to use gelatin and/or to use an oil which is substantially free of polyunsaturated fatty acids, i.e. oxidatively stable.
  • the gelled emulsion may be used as a delivery vehicle for calcium compounds, especially calcium carbonate, for use in the treatment or prophylaxis of osteoporosis.
  • the calcium compound e.g. a calcium salt (especially calcium carbonate) as described in WO00/28973 and WO96/09036, the contents of which are hereby incorporated by reference
  • a water or oil soluble calcium salt may be dissolved in the water or oil phase.
  • Calcium tablets for osteoporosis treatment are typically large, crunchable discs weighing well over a gram so as to provide a calcium dose of about 500 mg. These tablets are extremely difficult to swallow whole and if crunched or allowed to dissolve release calcium carbonate particles into the mouth which may provide a long-lasting, unpleasant mouthfeel. Such tablets are required daily by the elderly and, since they are difficult to consume, there is a resulting problem with patient compliance. By presenting the calcium within a soft, chewable gelled oil-in-water emulsion of the type described herein, it is made much easier for the patient to consume the large daily dose, generally in two or a single dose unit.
  • the calcium compound present in the tablets preferably has a mean particle size by volume of 0.5-25 ⁇ m, especially 1-20 ⁇ m, particularly 2-15 ⁇ m.
  • the daily calcium dose is preferably 500 to 2000 mg Ca, particularly 800 to 1500 mg Ca, especially about 1000 mg Ca.
  • vitamin D e.g. vitamin D 3
  • the daily dose is preferably 100 to 1500 IU, particularly 200 to 1000 IU, especially 400 to 900 IU.
  • a calcium to vitamin D ratio of 1 g Ca to 800-900 IU vitamin D is especially preferred.
  • the proportion of this dose per dose unit of the composition of the invention is typically 20-100%, preferably about 25%, about 50% or about 100%, especially about 50% or 100%.
  • the invention provides an oral pharmaceutical composition in dose unit form comprising a physiologically tolerable calcium compound within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, and wherein the calcium content per dose unit is at least 125 mg Ca, for example 125 to 2000 mg Ca, especially 400 to 1200 mg Ca.
  • the dose units of the compositions of the invention may be formed in conventional fashion, e.g. preparation of the emulsion and formation of the emulsion into a gelled mass for example by dosing into molds before gelation is complete or by cutting a gelled mass into individual dose units, and, if desired, coating the gelled dose units.
  • Emulsification and subsequent steps involving unpackaged gel are preferably effected under a non-oxidizing atmosphere, e.g. a nitrogen atmosphere.
  • the dose units are blister packed and accordingly it is especially desirable to use the blistered layer of the blister packaging as the mold.
  • the blister pack can then be foil sealed.
  • oxygen-impermeable foil packaging is especially preferred, e.g. as both laminate of a blister pack or as a single dose unit containing sachet.
  • Oxygen-impermeable foils e.g. metal/plastics laminates, are well known in the food and pharmaceuticals industries.
  • the invention provides the use of a drug substance for the manufacture of a composition according to the invention for use in a method of treatment of a human.
  • the invention provides a method of treatment of a human subject with an effective amount of a drug substance, said method comprising administering said substance to said subject orally in a composition according to the invention.
  • the invention provides a pharmaceutical package, preferably a blister pack or sachet, comprising a foil-encased composition according to the invention.
  • FIGS. 1 and 2 are graphs showing the omega-3 fatty acid concentration and composition of EPA and DHA respectively in total plasma delivered by three different administration forms;
  • FIGS. 3 and 4 are graphs showing the total amount of EPA and DHA taken up respectively, i.e. the area under the curve of the graphs in FIGS. 1 and 2 respectively.
  • An aqueous phase is formed from the following ingredients:
  • Sunflower oil (or alternatively an omega-3 ester (Omacor®) is emulsified with the aqueous phase in a weight ratio of 45:55 and the emulsion is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set.
  • the blister tray is thermally sealed with a metal/plastics foil cover sheet.
  • Example 1 The drugs listed in Table 1 below are dissolved or dispersed in the oil or water phases used in Example 1 (in the oil phase if lipophilic or in the aqueous phase if not) at the concentrations per dose unit set out in Table 1 before emulsions are produced, poured and allowed to set as in Example 1.
  • the set-gel dosage units are packaged as in Example 1.
  • the dose units are conveniently 250, 500 or 750 mg.
  • the dose units are conveniently 500, 1000, 1500, 2000, 2500 or 3000 mg.
  • the dose units are preferably at least 1000 mg.
  • Ibuprofen 100-1500 e.g. 200, 400, 600 and 800
  • Ketoprofen 12.5-300 e.g. 12.5, 50, 75, 100 and 200
  • Paracetamol 500-1000 Loratadine 10 Astemizole 10, 50 and 200
  • Dexochlorpheniramine 2-12 e.g. 2, 4, 6 and 8
  • Chlorpheniramine 4 Clemastine 1 and 2 (as fumarate, 1.34 and 2.68)
  • Diphenhydramine 25 and 50 Buspirone 5, 10, 15, and 30 Fluoxetine 5-90 e.g.
  • the selegiline, apomorphine, insulin and calcitonin dose units are preferably dissolved in the mouth rather than chewed/swallowed.
  • An aqueous phase is prepared using the following components:
  • Drug-free and drug-containing dose units are prepared using this aqueous phase analogously to Examples 1 and 2.
  • An aqueous phase is prepared according to Example 1 but with an additional 1% wt hydroxypropyl methyl cellulose. 1250 mg/mL calcium carbonate (Scoralite 1B from Scora SA, France) is dispersed in this aqueous phase whereafter an emulsion is formed with the addition of cod liver oil (1:1 by volume) containing dissolved vitamin D 3 . The emulsion is stirred until gelling begins whereafter it is dosed into moulds at a dose unit of 1250 mg CaCO 3 and 400 IU vitamin D 3 per dose unit. The dose units are sealed as in Example 1.
  • omega-3 fatty acids delivered by two different administration forms two different formulations of omega-3 food supplements.
  • omega-3 fatty acids (2.805 g eicosapentaenoic acid (EPA), 1.87 g docosahexaenoic acid (DHA)) in triglyceride form and 13 mg Vitamin E were administered to students of 18-28 years of age, in the form of either a soft gelled oil-in-water emulsion or as standard softgel capsules. Blood samples were collected after 0, 2, 3, 4, 6, 8 and 26 hours. The fatty acid concentration and composition in total plasma were measured.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • a and D correspond to administration of the soft-gelled oil-in-water emulsion of the present invention containing EPA or DHA respectively
  • B and E correspond to the administration of a standard omega-3 soft gel capsules containing a liquid marine phospholipid core
  • C and F correspond to the administration of standard omega-3 soft gel capsules containing a liquid triglyceride core.
  • lipophilic compounds e.g. the omega-3 fatty acids EPA and DHA
  • EPA and DHA are absorbed more quickly when administered in a soft gelled oil-in-water emulsion than when administered in the form of a standard soft gel capsule containing a liquid core.
  • An aqueous phase is formed from the following ingredients:
  • Sorbitan sesquiolate (or another emulsifier) is mixed with the oil (e.g. an omega-3 ester (Omacor®)) in a weight ratio of 5:95.
  • This oil phase is emulsified with the aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser (available from IKA).
  • a further aqueous phase is formed from the following ingredients:
  • the above water-in-oil emulsion is further emulsified with the further aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser and the water-in-oil-in-water emulsion (double emulsion) is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set.
  • the blister tray is thermally sealed with a metal/plastics foil cover sheet.
  • Example 6 The drugs listed in Table 2 below are dissolved or dispersed in the oil or water phases used in Example 6 at the concentrations per dose unit set out in Table 2 before emulsions are produced, poured and allowed to set as in Example 6. The set-gel dosage units are packaged as in Example 6.
  • Vitamin B Composition Double Emulsion
  • An aqueous phase is formed from the following ingredients:
  • Premix vitamin powder 11.8 wt % UF29278368 * Water ad 100 wt % * Supplemix Multivit-Tab containing among others Vitamin B1 base, Vitamin B2, Vitamin B6 base, Vitamin B9 and Vitamin B12
  • Sorbitan sesquiolate (or another emulsifier) is mixed with the oil (e.g. caprilic/capric triglyceride (fractionated coconut oil)) in a weight ratio of 5:95.
  • This oil phase is emulsified with the aqueous phase in a weight ratio of 50:50 using an ULTRA-TURRAX® high-performance disperser.
  • a further aqueous phase is formed from the following ingredients:
  • the above water-in-oil emulsion is further emulsified with the further aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser and the water-in-oil-in-water emulsion (double emulsion) is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set.
  • the blister tray is thermally sealed with a metal/plastics foil cover sheet.
  • An aqueous phase is prepared using the following components:
  • An oil phase is prepared using the following components:
  • the oil phase is emulsified with the aqueous phase in a weight ratio of 7:93.
  • the emulsion is mixed with calcium carbonate powder (Eskal 500 from Staubtechnik, particle size 4-14 ⁇ m, ca. 80% by volume ⁇ 10 ⁇ m) in a weight ratio of 1:1 to form a homogeneous solution and poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set.
  • the blister tray is thermally sealed with a metal/plastics foil cover sheet.
  • Analogous dose units produced without Vitamin D, did not have the gritty or dustlike taste of other commercially available tablets. Instead, said dose units tasted like fizzy candy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuing, divisional application of U.S. application Ser. No. 13/123,233, filed Apr. 7, 2011, which is the national stage completion application of PCT Application Number PCT/GB2009/002404, filed Oct. 8, 2009, which claims priority from Great Britain Application No. GB 0818473.1, filed Oct. 8, 2008. Each of these applications is incorporated by reference herein in its entirety.
This invention relates to oral pharmaceutical compositions comprising a soft, gelled oil-in-water emulsion containing a drug substance, preferably a lipophilic drug substance, but optionally a hydrophilic or amphiphilic drug substance, to processes for their preparation, and to their use.
Many drug substances, i.e. the physiologically active components of pharmaceutical compositions, are hydrophobic and as a result, when administered into the gastrointestinal tract, have poor uptake by the body. Besides being wasteful, this can mean that the patient has to take large or frequent doses, or that the drug substance has to be injected, a procedure that is more uncomfortable for the patient and that may require the cooperation of a doctor or nurse.
Moreover, when the unit dose of a drug substance is large, the oral unit dosage forms, e.g. tablets or capsules, may likewise be large and so difficult for elderly or young patients to swallow and moreover may cause a gagging reaction even with healthy adults. Accordingly, any therapeutic or prophylactic dosage regime which involves the consumption of large numbers of dose units or numbers of large, difficult to swallow, dose units is inherently at risk of patient non-compliance.
However, we have now found that lipophilic drug substances may be administered without these problems when contained within a piece of soft, chewable, gelled oil-in-water emulsion.
Moreover, we have found that the uptake of lipophilic compounds is increased by providing such compounds in the form of a soft, gelled oil-in-water emulsion.
Thus viewed from one aspect the invention provides an oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.
Viewed from a further aspect, the invention provides a process for preparing an oral pharmaceutical composition in unit dose form, which process comprises: forming an oil phase comprising a lipophilic drug substance dissolved or dispersed in a physiologically tolerable oil such as one comprising a polyunsaturated fatty acid ester, e.g. an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil, preferably an omega-3 acid ester, particularly an EPA ester, a docosahexaenoic acid (DHA) ester or a combination of EPA and DHA esters; forming an aqueous phase comprising an aqueous solution of a physiologically tolerable gelling agent; forming an oil-in-water emulsion with said oil phase and said aqueous phase, allowing said emulsion to gel to form a soft chewable mass; and, before, during or after gelling of said emulsion, dividing said emulsion into dose units.
Viewed from a further aspect, the invention provides an oral pharmaceutical composition in unit dose form, each unit dose comprising a hydrophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled water-in-oil-in-water double emulsion. Here a water-in-oil emulsion comprising the water soluble drug substance in the aqueous phase is further emulsified with an aqueous phase comprising an aqueous solution of a physiologically tolerable gelling agent. This is especially useful when the hydrophilic drug substances to be administrated have a strong, unpleasant taste.
Viewed from a further aspect, the invention provides a process for preparing an oral pharmaceutical composition in unit dose form, which process comprises: forming an oil phase comprising a physiologically tolerable oil such as one comprising a polyunsaturated fatty acid ester, e.g. an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil, preferably an omega-3 acid ester, particularly an EPA ester, a docosahexaenoic acid (DHA) ester or a combination of EPA and DHA esters; forming an aqueous phase comprising an aqueous solution of a hydrophilic drug substance dissolved or dispersed therein; forming a water-in-oil emulsion with said oil phase and said aqueous phase, forming an oil-in-water emulsion with said water-in-oil phase and a further aqueous phase, comprising an aqueous solution of a physiologically tolerable gelling agent, allowing said emulsion to gel to form a soft chewable mass; and, before, during or after gelling of said emulsion, dividing said emulsion into dose units.
The soft, gelled dose units of the present invention can remain intact during passage through the stomach and release the drug substances disposed within the gel matrix further down the gastrointestinal tract where the environment is not so harsh and where uptake is feasible. In this format some of the drug substance at the periphery of the matrix may be degraded by gastric fluid during stomach transit. Nonetheless, the soft, gelled dose units of the present invention have the advantage of being chewable and so more easily swallowed if large, e.g. above 1000 mg, more especially 1500 to 5000 mg. In the case where a large dose is required, the advantage of a single chewable dose unit may outweigh the relatively small loss of drug substance from the periphery of the chewed fragments during stomach transit. Chewable gel units moreover have the advantage that patient compliance is greater for patients with a gag reaction to swallowing tablets or capsules intact, in particular juvenile or elderly patients.
Thus viewed from one aspect the invention provides an oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion capable of remaining substantially intact during passage through the stomach.
Thus viewed from one aspect the invention provides an oral pharmaceutical composition in unit dose form, each unit dose comprising a hydrophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled water-in-oil-in-water double emulsion capable of remaining substantially intact during passage through the stomach.
By soft and chewable it is meant that the gelled emulsion is readily deformable rather than rigid while yet being self supporting, i.e. that it will not flow like a viscous liquid, and that it may be readily fragmented upon chewing, i.e. so that it need not be swallowed whole. Typically, such a gelled emulsion may be compressed, at least substantially reversibly, i.e. elastically, by at least 10%, preferably at least 40% upon application of a force/deformation gradient of 0.1 mm/s at 21° C., 50% relative humidity and atmospheric pressure.
Preferably the compression breaking strengths of the soft, gelled dose units of the present invention are greater than 500 g/cm2, particularly greater than 1000 g/cm2, especially preferably greater than 2000 g/cm2, e.g. 2900-3600 g/cm2.
By unitary carrier body, it is meant that each dose unit contains one piece of gelled emulsion. Such pieces may be referred to hereinafter as “cores”.
The cores may be formed from larger pieces of gelled emulsion, e.g. by cutting, or, more preferably by extrusion or molding of dose units of incompletely gelled emulsion.
By drug substance is meant a substance having a desirable therapeutic or prophylactic effect other than as a nutrient, i.e. substances of the type for which regulatory approval as a drug is required in for example the US or the European Union. Less preferably, the drug substance may be a vitamin which classifies as a drug substance for regulatory purposes, e.g. vitamin A, K or D (e.g. ergocalciferol, alphacalcidol and calcitriol). Vitamins, including these, as well as mineral and/or herbs may of course be included in the compositions in addition to non-vitamin drug substances.
By amphiphilic drug substance is meant a drug substance that will distribute at the oil droplet surface. In the single emulsion of the present invention the amphiphilic drug substance is mixed with the oil phase and in the double emulsion of the present invention the amphiphilic drug substance is mixed either with the oil or with the discontinuous aqueous phase of the double emulsion.
Examples of categories of suitable drug substances for use according to the invention include: analgesics; anti-inflammatories; anticancer agents; cardiovascular agents; biological agents; antiallergy agents (e.g. antihistamines); decongestants; antinausea agents, drugs affecting gastrointestinal function, drugs acting on the blood and blood-forming organs, drugs affecting renal and cardiovascular function, antifungal agents, urological agents, hormones, antimicrobial agents, antiepileptical agents, psycholeptical agents, antipsychotic agents, psychoanaleptical agents, anticholinesterase agents, drugs acting on the respiration organs and drugs acting on the eye.
Examples of particular lipophilic drug substances for use according to the invention include: temazepam; diphenhydramine; zolpidem; triazolam; nitrazepam; testosterone; estradiol; progesterone; benzodiazepines; barbiturates; cyclosporine; insulin; calcitonin; dextromethorphan; pseudoephedrine; phenylpropanolamine; bromocryptine; apomorphine; selegiline; amitriptyline; dextroamphetamine; phentermine; mazindol; compazine; chlorpromazine; perphenazine; fluoxetine, buspirone; clemastine; chlorpheniramine; dexochlorpheniramine; astemizole; loratadine; paracetamol; ketoprofen; naproxen; and, particularly, ibuprofen.
Examples of particular hydrophilic drug substances for use according to the invention include: sodium acetazolamide, acetyl salicylic acid, aminophylline, amiodarone hydrochloride, ascorbic acid, atenolol, bendroflumethiazide, calcium folinate, captopril, cetrizine hydrochloride, chloramphenicol sodium succinate, chlorpheniramine maleate, chlorpromazine hydrochloride, cimetidine hydrochloride, ciprofloxacin hydrochloride, clindamycin hydrochloride, clonidine hydrochloride, codeine phosphate, cyclizine hydrochloride, cyclophosphamide, sodium dexamethasone phosphate, sodium dicloxacillin, dicyclomide hydrochloride, diltiazem hydrochloride, diphenhydramine hydrochloride, disopyramide phosphate, doxepin hydrochloride, enalapril maleate, erythromycin ethylsuccinate, flecanide acetate, fluphenazine hydrochloride, folic acid, granisteron hydrochloride, guafenesin, haloperidol lactate, hydralazin hydrochloride, hydrochloroquine sulfate, hydromorphone hydrochloride, hydroxyzine hydrochloride, sodium indomethacin, isoniazid, isoprenaline hydrochloride, ketorolac trometamol, labetalol hydrochloride, lisinopril, lithium sulfate, mesoridazine benzylate, methadone hydrochloride, methylphenidate hydrochloride, methylprednisolone sodium succinate, metorprolol tartrate, metronidazole hydrochloride, methyldopa, mexiletine hydrochloride, molidone hydrochloride, morphine sulfate, naltrexone hydrochloride, neomycin sulfate, ondanstreon hydrochloride, orciprenaline sulfate, sodium oxacillin, oxybutynin chloride, oxycodone hydrochloride, paracetamol, penicillamine, pentoxifylline, petidine hydrochloride, sodium phenobarbital, potassium phenoxymethylpenicillin, phenylephrine hydrochloride, sodium phenyloin, potassium iodide, primaquine phosphate, procainamide hydrochloride, procarbazine hydrochloride, prochlorperazine maleate, promazine hydrochloride, promethazine hydrochloride, propranolol hydrochloride, pseudoephedrine hydrochloride, pyridostigmine bromide, pyridoxine hydrochloride, ranitidine hydrochloride, salbutamol sulfate, sodium ethacrynate, sotalol hydrochloride, sumatripan succinate, terbinafine hydrochloride, terbutaline sulfate, tetracycline hydrochloride, thioridazine hydrochloride, thiothixene hydrochloride, trifluoperazine hydrochloride, triprolidine hydrochloride, sodium valproate, vancomycin hydrochloride, vancomycin hydrochloride, verapamil hydrochloride, sodium warfarin.
The quantity of drug substance per unit dose of the compositions of the invention will conveniently be in the range of 50 to 200%, especially 80 to 120%, of the quantity per unit dose in conventional formulations of the drug substance or 25, 50 or 100% of the normal recommended daily adult or child dose. For ibuprofen, for example, the quantity per unit dose is preferably 100 to 1500 mg, especially 200 to 1200 mg, particularly 400 to 600 mg.
The compositions of the invention especially preferably consist of cores of gelled emulsion. However, less preferably, they may comprise a gelled emulsion core provided with a coating of a physiologically tolerable coating material. Such coatings may be of the type conventional within the pharmaceutical industry and may be applied by conventional means, e.g. spraying or dipping. For some applications, especially paediatric applications, a thin sugar (or otherwise sweetened) coating may be desired. Unless it is rapidly soluble in the mouth, however, rigid coatings are generally not desired since it is central to the invention that the soft gelled core be chewable so as to facilitate swallowing.
It is preferred that the cores be non-spherical as this facilitates chewing. While disc and lenticular forms are suitable, it is preferred that the cores be elongate, for example having cylindrical or similar form (optionally of course with rounded ends and one or more planar side faces). Where the application is paediatric, the cores may be in child-attractive forms, e.g. in a geometric shape or in the shape of an animal or cartoon character. In this way, the unit dose may be consumed with ease by patients who otherwise might have difficulty swallowing a conventional tablet or capsule, e.g. the young, the old, those with gag reactions, patients on chemotherapy, and others with reduced mouth function.
Since one major benefit of the compositions of the invention lies in their ease of consumption relative to conventional tablets or capsules, the cores will generally be quite large, e.g. having a mass of 100 to 3000 mg, especially 400 to 2000 mg, particularly 600 to 1500 mg. Where the drug substance dose per unit is quite small and the benefit of the invention lies in improved bioavailability, the cores may be smaller, e.g. as low as 50 mg, however even then larger cores may be used and in this event the compositions may be used as a source of beneficial oils, for example polyunsaturated fatty acid esters such as phospholipids, glycerides and lower alkyl (e.g. C1-6 alkyl, especially ethyl) esters. Preferred polyunsaturated acids in this regard include the omega-3 acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
The oil of the oil phase in the compositions of the invention may be any physiologically tolerable oil, such as one comprising a polyunsaturated fatty acid ester, e.g. an omega-3 acid ester, an omega-6 acid ester, an omega-9 acid ester or a vegetable oil, preferably an omega-3 acid ester, but will preferably be one or a mixture of fatty acid esters (for example phospholipids, mono-, di- or tri-glycerides, and lower alkyl esters). Such materials may be natural, synthetic or semi-synthetic. The use of plant and marine oils (e.g. oils from plant seeds, algae, fish (especially oily fish), microorgansims and marine invertebrates (especially krill)) is especially preferred as is the use of DHA and/or EPA ethyl esters. Mammalian oils will generally be undesired.
In one preferred embodiment, the oil of the oil phase may be a 90% mixture of ethyl EPA ester and ethyl DPA ester. This is available as Omacor® from Pronova Biocare AS, Lysaker, Norway.
Where the drug substance is not oxidation sensitive, it is generally preferred to use an oil which likewise is not oxidation sensitive since in this event the emulsion need not be guarded against oxidation during preparation or storage. Oils with low or no content of polyunsaturated acids may then be used. Where however the drug substance is oxidation sensitive, it may be preferred to use oils which are or majoritatively are polyunsaturated fatty acid esters, especially omega-3 esters, as these may function in part to reduce drug substance oxidation and as they may provide additional benefit to the consumer. Even where the drug substance is not oxidation sensitive, the use of oils which are or majoritatively are polyunsaturated fatty acid esters may be desirable, especially where such esters contribute to the beneficial effect of the drug, for example where the drug substance is a cardiovascular therapy or anticancer therapy agent.
Typically the oil phase will constitute 0.05 to 5 g, preferably 0.1 to 3 g, especially 0.2 to 2 g, particularly 0.3 to 1.25 g, more particularly 0.4 to 0.75 g, per dose unit. Alternatively put, the oil phase preferably constitutes 5 to 75% wt., especially at least 35 to 50% wt., e.g. 40 to 50% wt. of the dose unit.
The gelling agent used in the aqueous phase of the emulsion may be any physiologically tolerable gelling agent (preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein) or combination capable of forming a soft, chewable, self-supporting gelled oil-in-water emulsion. Many such materials are known from the food and pharmaceutical industry and are discussed for example in Handbook of hydrocolloids, G O Phillips and P A Williams (Eds.), Woodhead Publishing, Cambridge, UK, 2000. The gelling agents are preferably materials capable of undergoing a sol-gel transformation, e.g. under the influence of a change in physiochemical parameters such as temperature, pH, presence of metal ions (e.g. group 1 or 2 metal ions), etc. Preferred gelling agents include gelatins, alginates and carrageenans. However, the use of gelatins is especially preferred as breakdown in the throat of trapped fragments is ensured and as cores having the desired properties may readily be produced using gelatins.
Here it should be emphasized that the gelled emulsion should be self-supporting, soft and fragmentable on chewing. It is not desired that the gelled emulsion should dissolve rapidly in the mouth without chewing as the administration of the composition would then differ little functionally from administration of an oil solution of the drug. Gelatin can be used to give the gelled emulsions these desired characteristics.
The gelatins used as gelling agents in the composition of the invention may be produced from the collagen of any mammal or the collagen of any aquatic species, however the use of gelatin from salt-water fish and in particular cold and warm water fishes is preferred.
Gelatins having an imino acid content of 5 to 25% wt. are preferred, more especially those having an imino acid content of 10 to 25% wt. The gelatins will typically have a weight average molecular weight in the range 10 to 250 kDa, preferably 75 to 220 kDa, especially 80 to 200 kDa. Gelatins having no Bloom value or low Bloom values of 60-300, especially 90-200 are preferred. Where a gelatin of no Bloom value, e.g. a cold water fish gelatin, is used, this will typically be used together with another gelatin or other gelling agent. The combination of cold water and warm water fish gelatins is especially preferred. The gelatin will typically be present in the aqueous phase at a concentration of 1 to 50% wt., preferably 2 to 35% wt., particularly 5 to 25% wt. In the case of mixtures of gelatin and polysaccharides, the weight ratio of gelatin to polysaccharide in the aqueous phase will typically be 50:1 to 5:1, preferably 40:1 to 9:1, especially 20:1 to 10:1.
Where polysaccharides, or mixtures of polysaccharides and gelatin are used as the gelling agent, it is preferred to use natural polysaccharides, synthetic polysaccharides or semisynthetic polysaccharides, e.g. polysaccharides from plants, fish, terrestrial mammals, algae, bacteria and derivatives and fragmentation products thereof. Typical marine polysaccharides include carageenans, alginates, agars and chitosans. Typical plant polysaccharides include pectins. Typical microorganism polysaccharides include gellans and scleroglucans. The use of charged, e.g. electrostatically charged and/or sulfated polysaccharides is preferred, as is the use of marine polysaccharides, in particular carageenans, and alginates, especially carageenans. Carageenans are used below as representative polysaccharide gelling agents.
The carageenan family, which includes iota- and kappa-carageenans, is a family of linear sulfated polysaccharides produced from red algae. The repeating disaccharide unit in kappa-carrageenan is β-D-galactose-4-sulfate and 3,6-anhydro-α-D-galactose, while that in iota-carrageenan is β-D-galactose-4-sulfate and 3,6-anhydro-α-D-galactose-2-sulfate. Both kappa- and iota-carrageenans are used in food preparations. The carrageenans are used as stabilisers, emulsifiers, gelling agents and fat replacers.
Both iota and kappa carrageenans form salt- or cold-setting reversible gels in an aqueous environment. Coil-helix transition and aggregation of helices form the gel network. Kappa-carrageenan has binding sites for specific monovalent cations, resulting in gel formation with decreasing shear and elastic moduli in the order Cs+>K+>>Na+>Li+. As a rule, an increasing salt concentration enhances the elastic modulus and the setting and melting temperatures of a kappa-carrageenan gel. The use of water-soluble potassium, rubidium, or caesium compounds, particularly potassium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when kappa-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM, more especially up to 50 mM. A salt-dependent conformational transition is also found for iota-carrageenan. The molecules are also known to undergo coil-helix transition with strong helix-stabilisation in the presence of multivalent cations, like Ca2+. The use of water-soluble calcium, strontium, barium, iron or aluminium compounds, especially calcium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when iota-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM.
The polysaccharide gelling agents used according to the invention will typically have weight average molecular weights of 5 kDa to 2 MDa, preferably 10 kDa to 1 MDa, most preferably 100 kDa to 900 kDa, particularly 200 to 800 kDa. They will typically be used at concentrations of 0.01 to 5% wt, preferably 0.1 to 1.5% wt., particularly 0.2 to 1% wt in the aqueous phase. Where mono or multivalent cations, typically group 1 or group 2 metal ions, are included in the aqueous phase, this will typically be at concentrations in the range 2.5 to 100 mM, particularly 5 to 50 mM.
Besides the gelling agent and water and any required gelling initiator, other physiologically tolerable materials may be present in the aqueous phase, e.g. emulsifiers, emulsion stabilizers, pH modifiers, viscosity modifiers, sweeteners, fillers, vitamins (e.g. vitamin C, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, folacin, panthotenic acid), minerals, aromas, flavours, colours, physiologically active agents, etc. It is especially preferred that a lipophilic antioxidant, e.g. vitamin E, be included in the oil phase. Other vitamins which may be present in the oil phase are vitamin A, vitamin D and vitamin K. Such further components are used widely in the food, pharmaceutical and nutraceutical industries. The use of cellulose derivatives (e.g. hydroxy methyl propyl cellulose) as emulsion stabilizers is especially preferred.
The pH of the aqueous phase of the emulsion is preferably in the range 2 to 9, particularly 3 to 7.5.
The aqueous phase preferably has a gelling temperature in the range 10 to 30° C., more preferably 15 to 28° C., and a melting temperature in the range 20 to 80° C., more preferably 24 to 60° C., especially 28 to 50° C.
Where a sweetener is included in the aqueous phase, this will typically be selected from natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol and artificial sweeteners such as aspartame, acesulfame-K, neotame, saccharine, sucralose. The use of non-cariogenic sweeteners is preferred and the use of xylitol is especially preferred.
Where the drug substance is an analgesic, especially paracetamol or acetylsalicylic acid, or an antihistamine, it is preferred to use gelatin and/or to use an oil which is substantially free of polyunsaturated fatty acids, i.e. oxidatively stable.
Besides lipophilic drug substances, the gelled emulsion may be used as a delivery vehicle for calcium compounds, especially calcium carbonate, for use in the treatment or prophylaxis of osteoporosis. For this purpose, the calcium compound (e.g. a calcium salt (especially calcium carbonate) as described in WO00/28973 and WO96/09036, the contents of which are hereby incorporated by reference) may be dispersed in one or both of the oil and aqueous phases before or during gelation. Alternatively, a water or oil soluble calcium salt may be dissolved in the water or oil phase. In such compositions, it is especially desirable to include one or both of xylitol and vitamin D in the compositions, e.g. respectively in the water and oil phases.
Calcium tablets for osteoporosis treatment are typically large, crunchable discs weighing well over a gram so as to provide a calcium dose of about 500 mg. These tablets are extremely difficult to swallow whole and if crunched or allowed to dissolve release calcium carbonate particles into the mouth which may provide a long-lasting, unpleasant mouthfeel. Such tablets are required daily by the elderly and, since they are difficult to consume, there is a resulting problem with patient compliance. By presenting the calcium within a soft, chewable gelled oil-in-water emulsion of the type described herein, it is made much easier for the patient to consume the large daily dose, generally in two or a single dose unit.
The calcium compound present in the tablets preferably has a mean particle size by volume of 0.5-25 μm, especially 1-20 μm, particularly 2-15 μm.
Since tablet size is not an issue for the compositions of the invention, at least some of the calcium may be presented in dissolved form. (For solid, crunchable tablets, minimising tablet size to facilitate consumption has meant the presentation of the calcium as particulate calcium carbonate).
The daily calcium dose is preferably 500 to 2000 mg Ca, particularly 800 to 1500 mg Ca, especially about 1000 mg Ca. Where, as is preferred, vitamin D (e.g. vitamin D3) is co-administered, the daily dose is preferably 100 to 1500 IU, particularly 200 to 1000 IU, especially 400 to 900 IU. A calcium to vitamin D ratio of 1 g Ca to 800-900 IU vitamin D is especially preferred. The proportion of this dose per dose unit of the composition of the invention is typically 20-100%, preferably about 25%, about 50% or about 100%, especially about 50% or 100%.
Thus viewed from a further aspect the invention provides an oral pharmaceutical composition in dose unit form comprising a physiologically tolerable calcium compound within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, and wherein the calcium content per dose unit is at least 125 mg Ca, for example 125 to 2000 mg Ca, especially 400 to 1200 mg Ca.
The dose units of the compositions of the invention may be formed in conventional fashion, e.g. preparation of the emulsion and formation of the emulsion into a gelled mass for example by dosing into molds before gelation is complete or by cutting a gelled mass into individual dose units, and, if desired, coating the gelled dose units. Emulsification and subsequent steps involving unpackaged gel are preferably effected under a non-oxidizing atmosphere, e.g. a nitrogen atmosphere.
Particularly preferably the dose units are blister packed and accordingly it is especially desirable to use the blistered layer of the blister packaging as the mold. The blister pack can then be foil sealed. The use of oxygen-impermeable foil packaging is especially preferred, e.g. as both laminate of a blister pack or as a single dose unit containing sachet. Oxygen-impermeable foils, e.g. metal/plastics laminates, are well known in the food and pharmaceuticals industries.
Viewed from a further aspect the invention provides the use of a drug substance for the manufacture of a composition according to the invention for use in a method of treatment of a human.
Viewed from a further aspect the invention provides a method of treatment of a human subject with an effective amount of a drug substance, said method comprising administering said substance to said subject orally in a composition according to the invention.
Viewed from a still further aspect the invention provides a pharmaceutical package, preferably a blister pack or sachet, comprising a foil-encased composition according to the invention.
Embodiments of the invention will now be described in the following non-limiting examples and the accompanying drawings, in which:
FIGS. 1 and 2 are graphs showing the omega-3 fatty acid concentration and composition of EPA and DHA respectively in total plasma delivered by three different administration forms;
FIGS. 3 and 4 are graphs showing the total amount of EPA and DHA taken up respectively, i.e. the area under the curve of the graphs in FIGS. 1 and 2 respectively.
 EXAMPLE 1
Drug-Free Composition
An aqueous phase is formed from the following ingredients:
Gelatin 7.5% wt
Xylitol 36% wt
Sorbitol 14% wt
50% Citric acid 1% wt
Lemon flavour 0.15% wt
Water ad
100% wt
Sunflower oil (or alternatively an omega-3 ester (Omacor®) is emulsified with the aqueous phase in a weight ratio of 45:55 and the emulsion is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set. The blister tray is thermally sealed with a metal/plastics foil cover sheet.
EXAMPLE 2
Drug-Containing Compositions
The drugs listed in Table 1 below are dissolved or dispersed in the oil or water phases used in Example 1 (in the oil phase if lipophilic or in the aqueous phase if not) at the concentrations per dose unit set out in Table 1 before emulsions are produced, poured and allowed to set as in Example 1. The set-gel dosage units are packaged as in Example 1.
For drug concentrations below 100 mg per dose unit, the dose units are conveniently 250, 500 or 750 mg. For concentrations above 100 mg per dose unit, the dose units are conveniently 500, 1000, 1500, 2000, 2500 or 3000 mg. Where an omega-3 ester is used as the oil of the oil phase, the dose units are preferably at least 1000 mg.
TABLE 1
Drug substance Dose per dose unit (mg)
Ibuprofen 100-1500 (e.g. 200, 400, 600 and 800)
Naproxen 250, 375 and 500
Ketoprofen 12.5-300 (e.g. 12.5, 50, 75, 100 and 200)
Paracetamol 500-1000
Loratadine 10
Astemizole 10, 50 and 200
Dexochlorpheniramine 2-12 (e.g. 2, 4, 6 and 8)
Chlorpheniramine 4
Clemastine 1 and 2 (as fumarate, 1.34 and 2.68)
Diphenhydramine 25 and 50
Buspirone 5, 10, 15, and 30
Fluoxetine 5-90 (e.g. 10 and 20)
Perphenazine 2, 4, 8 and 16
Chlorpromazine 10, 25, 50, 100 and 200
Prochlorperazine 5, 10 and 15
Mazindol 1, 2 and 3
Phentermine 8-40 (e.g. 8, 15 and 30)
Dextroamphetamine 5, 10 and 15
Amitriptyline 10, 25, 50, 75, 100 and 150
Selegiline 1.25, 5 and 10
Apomorphine 5 and 10
Bromocryptine 2.5 to 40 (e.g. 2.5, 5, 10, 15)
Phenylpropanolamine 25, 50, 75, 400 and 600
Pseudoephedrine 60 and 120
Dextromethorphan 30-600 (e.g. 30, 90, 400)
Calcitonin 5, 30, 35, 75 and 150
Insulin Recommended daily dose
Cyclosporine 25 and 100
Barbiturate (butabarbital) 30, 50 and 100
Benzodiazepine (e.g. temazepam, 0.25, 0.5, 1 and 2
triazolam and nitrazepam)
Progesterone 100, 200 and 300
Estradiol (as estradiol valerinate) 0.5, 1 and 2
Testosterone (as testosterone 10
undecanoate)
Nitrazepam 0.3, 1, 2.5, 5 and 10
Triazolam 0.125, 0.25 and 0.5
Zolpidem 5 and 10
Temazepam 7.5, 15, 22.5 and 30
Ergocalciferol 10-200 kIU (e.g. 30000 IU)
Alphacalcidol 0.25, 0.5, 1 and 2 micrograms
Calcitriol 0.25, 0.5, 1 and 2 micrograms
The selegiline, apomorphine, insulin and calcitonin dose units are preferably dissolved in the mouth rather than chewed/swallowed.
EXAMPLE 3
Gum Arabicum-Containing Compositions
An aqueous phase is prepared using the following components:
Gelatin 5.7% wt
Xylitol 24.2% wt
Sorbitol 10.4% wt
50% Citric acid 0.6% wt
Lemon flavour 1.1% wt
Gum arabicum 3.7% wt
Water ad
100% wt
Drug-free and drug-containing dose units are prepared using this aqueous phase analogously to Examples 1 and 2.
EXAMPLE 4
Calcium Composition
An aqueous phase is prepared according to Example 1 but with an additional 1% wt hydroxypropyl methyl cellulose. 1250 mg/mL calcium carbonate (Scoralite 1B from Scora SA, France) is dispersed in this aqueous phase whereafter an emulsion is formed with the addition of cod liver oil (1:1 by volume) containing dissolved vitamin D3. The emulsion is stirred until gelling begins whereafter it is dosed into moulds at a dose unit of 1250 mg CaCO3 and 400 IU vitamin D3 per dose unit. The dose units are sealed as in Example 1.
EXAMPLE 5
Randomised, Controlled Trial
The absorption of omega-3 fatty acids delivered by two different administration forms (two different formulations of omega-3 food supplements) is compared.
5 g omega-3 fatty acids (2.805 g eicosapentaenoic acid (EPA), 1.87 g docosahexaenoic acid (DHA)) in triglyceride form and 13 mg Vitamin E were administered to students of 18-28 years of age, in the form of either a soft gelled oil-in-water emulsion or as standard softgel capsules. Blood samples were collected after 0, 2, 3, 4, 6, 8 and 26 hours. The fatty acid concentration and composition in total plasma were measured.
In FIGS. 1-4, A and D correspond to administration of the soft-gelled oil-in-water emulsion of the present invention containing EPA or DHA respectively, B and E correspond to the administration of a standard omega-3 soft gel capsules containing a liquid marine phospholipid core and C and F correspond to the administration of standard omega-3 soft gel capsules containing a liquid triglyceride core.
From FIGS. 1 and 2, it can be seen that lipophilic compounds (e.g. the omega-3 fatty acids EPA and DHA) are absorbed more quickly when administered in a soft gelled oil-in-water emulsion than when administered in the form of a standard soft gel capsule containing a liquid core.
From FIGS. 3 and 4, it can be seen that a higher total plasma concentration of lipophilic compounds (e.g. the omega-3 fatty acids EPA and DHA) is achieved when administered in a soft gelled oil-in-water emulsion than when administered in the form of a standard soft gel capsule containing a liquid core.
EXAMPLE 6
Ibuprofen Composition (Double Emulsion)
An aqueous phase is formed from the following ingredients:
Ibuprofen solution (50 (w/v) %)* 71.6 wt %
Flavouring 28.4 wt % *Solvent:
    • 50 (v/v) % water
    • 25 (v/v) % PEG (50 (w/v) %)
    • 25 (v/v) % KOH (50 (w/v) %)
Sorbitan sesquiolate (or another emulsifier) is mixed with the oil (e.g. an omega-3 ester (Omacor®)) in a weight ratio of 5:95. This oil phase is emulsified with the aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser (available from IKA).
A further aqueous phase is formed from the following ingredients:
Gelatin 17.2 wt %
Gum arabicum 4.2 wt %
Sorbitol 15.9 wt %
Xylitol 29.6 wt %
Na-Saccharin 0.1 wt %
Na-Cyclamate 0.9 wt %
Citric acid 0.9 wt %
Colouring 1.5 wt %
Water ad
100 wt %
The above water-in-oil emulsion is further emulsified with the further aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser and the water-in-oil-in-water emulsion (double emulsion) is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set. The blister tray is thermally sealed with a metal/plastics foil cover sheet.
EXAMPLE 7
Hydrophilic Drug-Containing Compositions
The drugs listed in Table 2 below are dissolved or dispersed in the oil or water phases used in Example 6 at the concentrations per dose unit set out in Table 2 before emulsions are produced, poured and allowed to set as in Example 6. The set-gel dosage units are packaged as in Example 6.
TABLE 2
Drug substance Dose per dose unit (mg)
Acetazolamide sodium 125
Acetyl salicylic acid 75
Aminophylline 100
Amiodarone hydrochloride 100
Ascorbic acid  25-100
Atenolol  25-100
Bendroflumethiazide  5-10
Calcium folinate  5-25
Captopril 12.5-100 
Cetrizine hydrochlorid 2.5-10 
Chloramphenicol sodium succinate 125
Chlorpheniramine maleate  2-12
Chlorpromazine hydrochloride  10-100
Cimetidine hydrochloride 100
Ciprofloxacin hydrochloride 100
Clindamycin hydrochloride  75-150
Clonidine hydrochloride 0.1-0.3
Codeine phosphate 15-60
Cyclizine hydrochloride  50-150
Cyclophosphamide 25-50
Dexamethasone sodium phosphate 0.25-6  
Dicloxacillin sodium 125
Dicyclomide hydrochloride 20
Diltiazem hydrochloride  30-120
Diphenhydramine hydrochloride 12.5-50  
Disopyramide phosphate 100
Doxepin hydrochloride  10-150
Enalapril maleate 2.5
Erythromycin ethylsuccinate 100
Flecanide acetate  50-150
Fluphenazine hydrochloride  1-10
Folic acid 0.4-1  
Granisteron hydrochloride 1
Guafenesin 100
Haloperidol lactate 0.5-20 
Hydralazin hydrochloride  10-100
Hydrochloroquine sulfate 200
Hydromorphone hydrochloride 1-8
Hydroxyzine hydrochloride  10-100
Indomethacin sodium 25-75
Isoniazid  50-100
Isoprenaline hydrochloride 10-15
Ketorolac trometamol 10
Labetalol hydrochloride 100
Lisinopril 2.5-40 
Lithium sulfate 42-83
Mesoridazine bensylate  10-100
Methadone hydrochloride  5-40
Methylphenidate hydrochloride  5-20
Methylprednisolone sodium succinate  2-32
Metorprolol tartrate  50-100
Metronidazole hydrochloride 250
Metyldopa 125
Mexiletine hydrochloride 150
Molidone hydrochloride  5-100
Morphine sulfate  15-200
Naltrexone hydrochloride 50
Neomycin sulfate 125
Ondanstreon hydrochloride 4-8
Orciprenaline sulfate 10-20
Oxacillin sodium 250
Oxybutynin chloride 5
Oxycodone hydrochloride  5-80
Paracetamol  80-160
Penicillamine 125
Pentoxifylline 400
Petidine hydrochloride  50-100
Phenobarbital sodium  15-100
Phenoxymethylpenicillin potassium 125
Phenylephrine hydrochloride 10
Phenytoin sodium  50-100
Potassium iodide 130
Primaquine phosphate 15
Procainamide hydrochloride 250
Procarbazine hydrochloride 50
Prochlorperazine maleate  5-30
Promazine hydrochloride 25-50
Promethazine hydrochloride 12.5-50  
Propranolol hydrochloride  10-160
Pseudoephedrine hydrochloride  30-120
Pyridostigmine bromide  60-180
Pyridoxine hydrochloride  10-200
Ranitidine hydrochloride  75-150
Salbutamol sulfate 2-8
Sodium ethacrynate 25-50
Sotalol hydrochloride  80-160
Sumatripan succinate 25-50
Terbinafine hydrochloride 250
Terbutaline sulfate 2.5-5  
Tetracycline hydrochloride 125
Thioridazine hydrochloride  10-150
Thiothixene hydrochloride  1-20
Trifluoperazine hydrochloride  1-10
Triprolidine hydrochloride 2.5
Valproate sodium 125
Vancomycin hydrochloride 125
Verapamil hydrochloride  40-120
Warfarin sodium  1-10
EXAMPLE 8
Vitamin B Composition (Double Emulsion)
An aqueous phase is formed from the following ingredients:
Premix vitamin powder 11.8 wt %
UF29278368 *
Water ad 100 wt %
* Supplemix Multivit-Tab containing among others Vitamin B1 base, Vitamin B2, Vitamin B6 base, Vitamin B9 and Vitamin B12
Sorbitan sesquiolate (or another emulsifier) is mixed with the oil (e.g. caprilic/capric triglyceride (fractionated coconut oil)) in a weight ratio of 5:95. This oil phase is emulsified with the aqueous phase in a weight ratio of 50:50 using an ULTRA-TURRAX® high-performance disperser.
A further aqueous phase is formed from the following ingredients:
Gelatin 17.2 wt %
Gum arabicum 4.2 wt %
Sorbitol 15.9 wt %
Xylitol 29.6 wt %
Na-Saccharin 0.1 wt %
Na-Cyclamate 0.9 wt %
Citric acid 0.9 wt %
Colouring 1.5 wt %
Water ad
100 wt %
The above water-in-oil emulsion is further emulsified with the further aqueous phase in a weight ratio of 69:31 using an ULTRA-TURRAX® high-performance disperser and the water-in-oil-in-water emulsion (double emulsion) is poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set. The blister tray is thermally sealed with a metal/plastics foil cover sheet.
EXAMPLE 9
Calcium and Vitamin D Composition
An aqueous phase is prepared using the following components:
Gelatin 9.1% wt
Xylitol 38.7% wt
Sorbitol 16.6% wt
Citric acid 0.9% wt
Gum arabicum 5.9% wt
Water ad
100% wt
An oil phase is prepared using the following components:
Flavouring 25% wt
Vitamin D 0.03% wt
Colouring
5% wt
Sunflower oil* ad 100% wt
*or alternatively an omega-3 ester(Omacor ®)
The oil phase is emulsified with the aqueous phase in a weight ratio of 7:93. The emulsion is mixed with calcium carbonate powder (Eskal 500 from Staubtechnik, particle size 4-14 μm, ca. 80% by volume<10 μm) in a weight ratio of 1:1 to form a homogeneous solution and poured in aliquots of 1.5 g into elongate moulds lined with a metal/plastics laminate blister tray and allowed to set. The blister tray is thermally sealed with a metal/plastics foil cover sheet.
Analogous dose units, produced without Vitamin D, did not have the gritty or dustlike taste of other commercially available tablets. Instead, said dose units tasted like fizzy candy.

Claims (6)

The invention claimed is:
1. An oral pharmaceutical composition in dose unit form comprising a physiologically tolerable calcium compound within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, wherein the calcium compound is dispersed in one or both of the oil and aqueous phases of the emulsion, and wherein the calcium content per dose unit is at least 125 mg Ca, and further wherein the aqueous phase comprises gelatin as a gelling agent in an amount of 5 to 50% wt. of the aqueous phase, and the weight of said dose unit is 1,000 mg to 5,000 mg.
2. A composition as claimed in claim 1 containing particulate calcium carbonate.
3. A composition as claimed in claim 1 further containing xylitol.
4. A composition as claimed in claim 1 consisting of a said gelled emulsion containing said calcium compound.
5. A pharmaceutical package comprising a composition as claimed in claim 1, wherein said composition is foil-encased.
6. A package as claimed in claim 5 in the form of a blister pack.
US14/515,297 2008-10-08 2014-10-15 Chewable gelled emulsions Active US9724296B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/515,297 US9724296B2 (en) 2008-10-08 2014-10-15 Chewable gelled emulsions
US15/639,047 US10668013B2 (en) 2008-10-08 2017-06-30 Chewable gelled emulsions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0818473.1A GB0818473D0 (en) 2008-10-08 2008-10-08 Composition
GB0818473.1 2008-10-08
PCT/GB2009/002404 WO2010041015A2 (en) 2008-10-08 2009-10-08 Chewable gelled emulsions
US201113123233A 2011-06-28 2011-06-28
US14/515,297 US9724296B2 (en) 2008-10-08 2014-10-15 Chewable gelled emulsions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2009/002404 Division WO2010041015A2 (en) 2008-10-08 2009-10-08 Chewable gelled emulsions
US13/123,233 Division US20110268771A1 (en) 2008-10-08 2009-10-08 Chewable gelled emulsions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/639,047 Continuation US10668013B2 (en) 2008-10-08 2017-06-30 Chewable gelled emulsions

Publications (2)

Publication Number Publication Date
US20150037438A1 US20150037438A1 (en) 2015-02-05
US9724296B2 true US9724296B2 (en) 2017-08-08

Family

ID=40042514

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/123,233 Abandoned US20110268771A1 (en) 2008-10-08 2009-10-08 Chewable gelled emulsions
US14/515,297 Active US9724296B2 (en) 2008-10-08 2014-10-15 Chewable gelled emulsions
US15/639,047 Active US10668013B2 (en) 2008-10-08 2017-06-30 Chewable gelled emulsions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/123,233 Abandoned US20110268771A1 (en) 2008-10-08 2009-10-08 Chewable gelled emulsions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/639,047 Active US10668013B2 (en) 2008-10-08 2017-06-30 Chewable gelled emulsions

Country Status (9)

Country Link
US (3) US20110268771A1 (en)
EP (3) EP2346490A2 (en)
JP (1) JP5685540B2 (en)
CA (3) CA2742966A1 (en)
ES (2) ES2919148T3 (en)
GB (1) GB0818473D0 (en)
IL (1) IL212196A0 (en)
PL (2) PL2952176T3 (en)
WO (1) WO2010041015A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016359B2 (en) 2022-11-11 2024-06-25 Pharmavite Llc Oil-in-water emulsion gummy composition with water soluble active ingredient(s)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
CN102510726A (en) * 2009-09-16 2012-06-20 森永制果株式会社 Soft candy and soft candy production method
GB201006178D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
GB201006214D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
GB201016900D0 (en) 2010-10-06 2010-11-17 Probio Asa Emulsion
EP2696846B1 (en) * 2011-04-11 2018-01-17 Vitux Group AS Oral pharmaceutical dispersion compositions
JP6004515B2 (en) * 2012-02-20 2016-10-12 国立研究開発法人海洋研究開発機構 Method for measuring enzyme activity
EP2827839B1 (en) 2012-03-20 2019-02-27 Particle Dynamics International, LLC Gelling agent-based dosage form
WO2015074898A1 (en) * 2013-11-19 2015-05-28 Qiagen Gmbh Method for generating emulsions
JP6877923B2 (en) * 2016-09-06 2021-05-26 ライオン株式会社 Semi-solid preparation for internal use and its manufacturing method
EP3599892B1 (en) * 2017-03-20 2024-04-03 Bayer Healthcare LLC Chewable gel products for active pharmaceutical ingredients
US20200016066A1 (en) * 2018-07-12 2020-01-16 Food Technology and Design, LLC, DBA FoodPharma Saccharide-based oral mucoadhesive delivery system for neurotrophic and neuroprotective compositions
US20210267886A1 (en) * 2018-06-29 2021-09-02 Nippon Shokubai Co., Ltd. Gel-In-Oil Emulsion and Transdermally Absorbed Agent
FR3085849B1 (en) * 2018-09-17 2021-01-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE
CN110478312A (en) * 2019-08-29 2019-11-22 仙乐健康科技股份有限公司 Stable gel composition and its preparation method and application with high fat content
GB201916960D0 (en) * 2019-11-21 2020-01-08 Vitus Group As Compositions
GB202202754D0 (en) 2022-02-28 2022-04-13 Vitux Group As Compositions

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474629A (en) 1973-08-07 1977-05-25 Uncle Ben S Australia Pty Proteinaceous food product and method of manufacture therefor
GB2086835A (en) 1980-11-10 1982-05-19 Damon Corp A method of encapsulating oils and oilsoluble materials
US4428927A (en) 1981-05-11 1984-01-31 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
JPS61277630A (en) 1985-06-01 1986-12-08 Morinaga Milk Ind Co Ltd Breeding of animal
US4695450A (en) 1982-10-12 1987-09-22 Warner Lambert Company Anhydrous emulsions and the use thereof
US4764383A (en) 1985-10-21 1988-08-16 Michael Drebot Soft homogenous fish bait
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US4961939A (en) 1989-06-02 1990-10-09 Nabisco Brands, Inc. Deodorized water-in-oil emulsion containing fish oil
US5004611A (en) 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
EP0474261A2 (en) 1987-11-25 1992-03-11 Meiji Seika Kaisha Ltd. Production of gelatin jelly confections
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
JPH05238954A (en) 1992-02-26 1993-09-17 Toyo Capsule Kk Carrier suitable for chewing administration
US5258184A (en) 1988-06-03 1993-11-02 Unilever Patent Holdings B.V. Emulsions
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
WO1996009036A1 (en) 1994-09-23 1996-03-28 Laboratoire Innothera, Societe Anonyme Therapeutic vitamin-calcium combination in unitary galenic tablet form, method for preparing same and use thereof
WO1996018387A1 (en) 1994-12-16 1996-06-20 Watson Laboratories, Inc. Chewable dosage forms
US5549204A (en) 1992-02-26 1996-08-27 Toren Consulting Pty. Ltd. Blister packs
JPH09224578A (en) 1996-02-20 1997-09-02 Nippon Synthetic Chem Ind Co Ltd:The Jelly candy including gamma-linolenic acid and its production
JPH1156315A (en) 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Gamma-linolenic acid-containing drink
JPH1156245A (en) 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Jelly candy containing oil and fat and its production
US5879698A (en) * 1994-09-26 1999-03-09 American Cyanamid Company Calcium dietary supplement
WO1999018967A1 (en) 1997-10-15 1999-04-22 Panos Therapeutics Limited Analgesic compositions
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
EP0950402A2 (en) 1998-02-23 1999-10-20 McNEIL-PPC, Inc. Chewable pharmaceutical composition with gelatin matrix
JP2000080027A (en) 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd Sustained release preparation
WO2000028973A1 (en) 1998-11-13 2000-05-25 Nycomed Pharma As Process for preparing oral calcium compositions
JP2000279107A (en) 1999-03-30 2000-10-10 Lion Corp Noncariogenic easy deglutition composition and food composition and medical composition using the same
US20010036468A1 (en) 1998-07-25 2001-11-01 Sam-A-Pharmaceuticals Co., Ltd. Soft chewable multivitamin tablet comprising separated active ingredients
WO2002024165A2 (en) 2000-09-20 2002-03-28 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
WO2002043659A2 (en) 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
JP2002524062A (en) 1998-09-02 2002-08-06 ナチュラル ポリマー インターナショナル コーポレイション Chewing toys for protein pets
WO2003018186A1 (en) 2001-08-23 2003-03-06 Bio-Dar Ltd. Stable coated microcapsules
US20030068407A1 (en) 1999-12-23 2003-04-10 Veronique Chiavazza Particulate vitamin composition
US20030099761A1 (en) * 2001-11-26 2003-05-29 Rolf Jost Shelf stable nutritional composition containing intact whey protein, process of manufacture and use
WO2003053159A1 (en) 2001-12-20 2003-07-03 Societe Des Produits Nestle S.A. A food product containing gel capsules or tablets
US20030158265A1 (en) 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
US20030166670A1 (en) 2002-02-15 2003-09-04 Howard Brooks-Korn Use of an opioid compound to treat a neurologic or neurogenic disorder
US20040001873A1 (en) 2002-07-01 2004-01-01 Base Marvin Dimitrios Gelled delivery vehicle containing nutritional ingredients
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
EP1189620B1 (en) 1999-04-01 2004-06-23 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil
US20040121000A1 (en) 2001-01-17 2004-06-24 Dennis Bowe Ingestible compositions containing an odoriferous oil
WO2004054539A1 (en) 2002-12-16 2004-07-01 The Boots Company Plc Medicinal compositions comprising a core and a film based on modified cellulose derivatives
JP2004194514A (en) 2002-12-16 2004-07-15 Biomedeikusu:Kk Medicine palatable for pet
JP2004238419A (en) 2003-02-03 2004-08-26 Bridgestone Corp Adhesive rubber composition
US20040248974A1 (en) 2001-09-07 2004-12-09 Christina Holmberg Self emulsifying drug delivery system
WO2005013714A1 (en) 2003-07-30 2005-02-17 Novartis Ag Palatable ductile chewable veterinary composition
US20050152968A1 (en) 2004-01-09 2005-07-14 Brophy Kristine M. Microemulsions for pharmaceutical compositions
WO2005084647A1 (en) 2004-03-08 2005-09-15 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical composition comprising pimobendan
JP2005527204A (en) 2002-04-05 2005-09-15 ネステク ソシエテ アノニム Methods and dietary compositions for improving lipid digestibility
WO2005105290A1 (en) 2004-04-21 2005-11-10 E.I. Dupont De Nemours And Company Encapsulation of oils by coacervation
US20050281748A1 (en) 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20060034815A1 (en) 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
WO2006019140A1 (en) 2004-08-18 2006-02-23 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2006021293A1 (en) 2004-08-23 2006-03-02 Unilever N.V. Composition comprising statin
US20060062810A1 (en) 2002-11-08 2006-03-23 Jong-Soo Woo Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same
US20060088645A1 (en) 2004-10-22 2006-04-27 Access Business Group International Llc Omega-3 food product and related method of manufacture
WO2006065675A2 (en) 2004-12-17 2006-06-22 The Regents Of The University Of California Method and compositions for preparing and delivering lipids, other nutrients and medicaments
WO2006096806A2 (en) 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2006106344A2 (en) 2005-04-06 2006-10-12 Mw Encap Limited Abuse resistant capsules
US20060233873A1 (en) 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
US20070026075A1 (en) 2005-07-28 2007-02-01 Jutaro Shudo Gelled donepezil compositions and methods for making and using the same
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
WO2007060177A1 (en) 2005-11-22 2007-05-31 Nestec S.A. Oil-in-water emulsion and its use for the delivery of functionality
US20070128142A1 (en) 2003-11-13 2007-06-07 Ian Harrison Emulsion for conveying a hydrophobic active material to a substrate in aqueous medium
US20070131342A1 (en) 2005-12-08 2007-06-14 Kimberly-Clark Worldwide, Inc. Method of making, using and applying a composition to an exposed surface
US20070141138A1 (en) 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
EP1803440A1 (en) 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
WO2007085835A1 (en) 2006-01-25 2007-08-02 Probio Nutraceuticals As Chewable capsules
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20070202049A1 (en) 2005-06-13 2007-08-30 Flamel Technologies, Inc. Oral dosage form comprising an antimisuse system
US20070213234A1 (en) 2004-05-18 2007-09-13 Nestec S.A. Oil-in-water emulsion for delivery
US20080008742A1 (en) 2006-06-29 2008-01-10 Capricorn Pharma, Inc. Chewy products and methods for making the same
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1946755A1 (en) 2005-11-11 2008-07-23 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2009053824A1 (en) 2007-10-23 2009-04-30 Laboratorio Chimico Internazionale S.P.A. Lipoic acid pellet composition
US20090130221A1 (en) 2006-03-29 2009-05-21 Fiona Bolland Decellularisation of tissue matrices for bladder implantation
WO2009095670A1 (en) 2008-01-29 2009-08-06 Ayanda As Soft gel capsules
US20090325895A1 (en) 2001-12-13 2009-12-31 Longgui Wang Methods of treating an inflammatory-related disease
WO2010041015A2 (en) 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
WO2010041017A2 (en) 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
US20100249045A1 (en) 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
WO2011128634A2 (en) 2010-04-14 2011-10-20 Probio Asa Over the counter pharmaceutical compositions
JP5238954B2 (en) 2008-02-29 2013-07-17 株式会社大一商会 Game machine
US20130274280A1 (en) 2010-04-14 2013-10-17 Ayanda Group As Anti-abuse gelled pharmaceutical compositions
US20130273025A1 (en) 2010-04-14 2013-10-17 Ayanda Group As Oral veterinary pharmaceutical and nutraceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS537492B2 (en) * 1973-02-12 1978-03-18
JPS5238954B2 (en) 1975-03-04 1977-10-01
SE9502370D0 (en) * 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
NO20021592D0 (en) * 2002-04-04 2002-04-04 Fmc Biopolymer As Polysaccharide Capsules and Method of Preparation thereof
AU2006200464A1 (en) 2005-02-08 2006-08-24 Nec Australia Pty Ltd Interference cancellation in a spread spectrum receiver
US20090196832A1 (en) * 2008-01-31 2009-08-06 Esteban Lakos Novel edible aqueous aerosol foam

Patent Citations (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474629A (en) 1973-08-07 1977-05-25 Uncle Ben S Australia Pty Proteinaceous food product and method of manufacture therefor
GB2086835A (en) 1980-11-10 1982-05-19 Damon Corp A method of encapsulating oils and oilsoluble materials
US4428927A (en) 1981-05-11 1984-01-31 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
US4695450A (en) 1982-10-12 1987-09-22 Warner Lambert Company Anhydrous emulsions and the use thereof
US5004611A (en) 1984-03-08 1991-04-02 Phares Pharmaceutical Research Nv Pro-liposome compositions
JPS61277630A (en) 1985-06-01 1986-12-08 Morinaga Milk Ind Co Ltd Breeding of animal
US4764383A (en) 1985-10-21 1988-08-16 Michael Drebot Soft homogenous fish bait
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
EP0474261A2 (en) 1987-11-25 1992-03-11 Meiji Seika Kaisha Ltd. Production of gelatin jelly confections
US5258184A (en) 1988-06-03 1993-11-02 Unilever Patent Holdings B.V. Emulsions
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US4961939A (en) 1989-06-02 1990-10-09 Nabisco Brands, Inc. Deodorized water-in-oil emulsion containing fish oil
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
JPH05238954A (en) 1992-02-26 1993-09-17 Toyo Capsule Kk Carrier suitable for chewing administration
US5549204A (en) 1992-02-26 1996-08-27 Toren Consulting Pty. Ltd. Blister packs
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
WO1996009036A1 (en) 1994-09-23 1996-03-28 Laboratoire Innothera, Societe Anonyme Therapeutic vitamin-calcium combination in unitary galenic tablet form, method for preparing same and use thereof
US5879698A (en) * 1994-09-26 1999-03-09 American Cyanamid Company Calcium dietary supplement
WO1996018387A1 (en) 1994-12-16 1996-06-20 Watson Laboratories, Inc. Chewable dosage forms
JPH09224578A (en) 1996-02-20 1997-09-02 Nippon Synthetic Chem Ind Co Ltd:The Jelly candy including gamma-linolenic acid and its production
JPH1156315A (en) 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Gamma-linolenic acid-containing drink
JPH1156245A (en) 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Jelly candy containing oil and fat and its production
WO1999018967A1 (en) 1997-10-15 1999-04-22 Panos Therapeutics Limited Analgesic compositions
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
EP0950402A2 (en) 1998-02-23 1999-10-20 McNEIL-PPC, Inc. Chewable pharmaceutical composition with gelatin matrix
US20010036468A1 (en) 1998-07-25 2001-11-01 Sam-A-Pharmaceuticals Co., Ltd. Soft chewable multivitamin tablet comprising separated active ingredients
JP2000080027A (en) 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd Sustained release preparation
JP2002524062A (en) 1998-09-02 2002-08-06 ナチュラル ポリマー インターナショナル コーポレイション Chewing toys for protein pets
WO2000028973A1 (en) 1998-11-13 2000-05-25 Nycomed Pharma As Process for preparing oral calcium compositions
JP2000279107A (en) 1999-03-30 2000-10-10 Lion Corp Noncariogenic easy deglutition composition and food composition and medical composition using the same
EP1189620B1 (en) 1999-04-01 2004-06-23 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil
US20030068407A1 (en) 1999-12-23 2003-04-10 Veronique Chiavazza Particulate vitamin composition
WO2002024165A2 (en) 2000-09-20 2002-03-28 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
US20040043043A1 (en) 2000-09-20 2004-03-04 Schlyter Jimmy Hirschsprung Preparation of emulsions and concentrates thereof
WO2002043659A2 (en) 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
US20040121000A1 (en) 2001-01-17 2004-06-24 Dennis Bowe Ingestible compositions containing an odoriferous oil
JP2004520355A (en) 2001-01-17 2004-07-08 アール．ピー． シェーラー テクノロジーズ インコーポレイテッド Ingestible composition containing odorous oil
JP2005500157A (en) 2001-08-23 2005-01-06 バイオ−ダール・リミテツド Coated stable microcapsule
WO2003018186A1 (en) 2001-08-23 2003-03-06 Bio-Dar Ltd. Stable coated microcapsules
US20040248974A1 (en) 2001-09-07 2004-12-09 Christina Holmberg Self emulsifying drug delivery system
US20030099761A1 (en) * 2001-11-26 2003-05-29 Rolf Jost Shelf stable nutritional composition containing intact whey protein, process of manufacture and use
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US20090325895A1 (en) 2001-12-13 2009-12-31 Longgui Wang Methods of treating an inflammatory-related disease
WO2003053159A1 (en) 2001-12-20 2003-07-03 Societe Des Produits Nestle S.A. A food product containing gel capsules or tablets
JP2005512552A (en) 2001-12-20 2005-05-12 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Food containing gel capsules or tablets
US20030166670A1 (en) 2002-02-15 2003-09-04 Howard Brooks-Korn Use of an opioid compound to treat a neurologic or neurogenic disorder
US20030158265A1 (en) 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
JP2005527204A (en) 2002-04-05 2005-09-15 ネステク ソシエテ アノニム Methods and dietary compositions for improving lipid digestibility
US20040001873A1 (en) 2002-07-01 2004-01-01 Base Marvin Dimitrios Gelled delivery vehicle containing nutritional ingredients
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US20060062810A1 (en) 2002-11-08 2006-03-23 Jong-Soo Woo Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same
JP2004194514A (en) 2002-12-16 2004-07-15 Biomedeikusu:Kk Medicine palatable for pet
US20060165795A1 (en) 2002-12-16 2006-07-27 Kirsty Sawicka Medicinal compositions comprising a core and a film based on modified cellulose derivatives
WO2004054539A1 (en) 2002-12-16 2004-07-01 The Boots Company Plc Medicinal compositions comprising a core and a film based on modified cellulose derivatives
US20060233873A1 (en) 2003-01-24 2006-10-19 Julien Meissonnier Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
JP2004238419A (en) 2003-02-03 2004-08-26 Bridgestone Corp Adhesive rubber composition
JP2007500004A (en) 2003-07-30 2007-01-11 ノバルティス アクチエンゲゼルシャフト A chewy, ductile, chewable veterinary composition
WO2005013714A1 (en) 2003-07-30 2005-02-17 Novartis Ag Palatable ductile chewable veterinary composition
US20070128142A1 (en) 2003-11-13 2007-06-07 Ian Harrison Emulsion for conveying a hydrophobic active material to a substrate in aqueous medium
WO2005070399A1 (en) 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
US20050152968A1 (en) 2004-01-09 2005-07-14 Brophy Kristine M. Microemulsions for pharmaceutical compositions
WO2005084647A1 (en) 2004-03-08 2005-09-15 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical composition comprising pimobendan
JP2007526269A (en) 2004-03-08 2007-09-13 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising pimobendan
WO2005105290A1 (en) 2004-04-21 2005-11-10 E.I. Dupont De Nemours And Company Encapsulation of oils by coacervation
US20070213234A1 (en) 2004-05-18 2007-09-13 Nestec S.A. Oil-in-water emulsion for delivery
US20050281748A1 (en) 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20060034815A1 (en) 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
EP1782807A1 (en) 2004-08-18 2007-05-09 Mochida Pharmaceutical Co., Ltd. Jelly composition
US20070259957A1 (en) 2004-08-18 2007-11-08 Hiroki Ueshima Jelly Composition
JP4943849B2 (en) 2004-08-18 2012-05-30 持田製薬株式会社 Jelly composition
WO2006019140A1 (en) 2004-08-18 2006-02-23 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2006021293A1 (en) 2004-08-23 2006-03-02 Unilever N.V. Composition comprising statin
EP1803440A1 (en) 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
JP2006115831A (en) 2004-10-22 2006-05-11 Access Business Group Internatl Llc omega-3 FOOD AND METHOD FOR PRODUCING THE SAME
US20060088645A1 (en) 2004-10-22 2006-04-27 Access Business Group International Llc Omega-3 food product and related method of manufacture
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
WO2006065675A2 (en) 2004-12-17 2006-06-22 The Regents Of The University Of California Method and compositions for preparing and delivering lipids, other nutrients and medicaments
WO2006096806A2 (en) 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
US20060211763A1 (en) 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
WO2006106344A2 (en) 2005-04-06 2006-10-12 Mw Encap Limited Abuse resistant capsules
US20090123386A1 (en) 2005-04-06 2009-05-14 Victor Morrison Young Abuse Resistant Capsules
US20070202049A1 (en) 2005-06-13 2007-08-30 Flamel Technologies, Inc. Oral dosage form comprising an antimisuse system
WO2007018801A1 (en) 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
US20070026075A1 (en) 2005-07-28 2007-02-01 Jutaro Shudo Gelled donepezil compositions and methods for making and using the same
US20100249045A1 (en) 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
EP1946755A1 (en) 2005-11-11 2008-07-23 Mochida Pharmaceutical Co., Ltd. Jelly composition
WO2007060177A1 (en) 2005-11-22 2007-05-31 Nestec S.A. Oil-in-water emulsion and its use for the delivery of functionality
US20080255247A1 (en) 2005-11-22 2008-10-16 Nestec S.A. Oil-In-Water Emulsion and Its Use for the Delivery of Functionality
US20070131342A1 (en) 2005-12-08 2007-06-14 Kimberly-Clark Worldwide, Inc. Method of making, using and applying a composition to an exposed surface
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
US20070141138A1 (en) 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
US20080268042A1 (en) 2005-12-20 2008-10-30 Cenestra Llc Omega 3 fatty acid formulations
US20100112047A1 (en) 2005-12-20 2010-05-06 Cenestra Llc Omega 3 fatty acid formulations
US20090238866A1 (en) 2006-01-25 2009-09-24 Probio Nutraceuticals As Chewable capsules
WO2007085835A1 (en) 2006-01-25 2007-08-02 Probio Nutraceuticals As Chewable capsules
JP2009526760A (en) 2006-01-25 2009-07-23 アヤンダ エーエス emulsion
WO2007085840A1 (en) 2006-01-25 2007-08-02 Probio Nutraceuticals As Emulsion
US20090220576A1 (en) 2006-01-25 2009-09-03 Probio Nutraceuticals As Emulsion
US20090130221A1 (en) 2006-03-29 2009-05-21 Fiona Bolland Decellularisation of tissue matrices for bladder implantation
WO2008005318A2 (en) 2006-06-29 2008-01-10 Capricorn Pharma Inc. Chewy products and methods for making the same
US20080008742A1 (en) 2006-06-29 2008-01-10 Capricorn Pharma, Inc. Chewy products and methods for making the same
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2008045170A2 (en) 2006-10-10 2008-04-17 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US20110303573A1 (en) 2006-12-20 2011-12-15 Cenestra Llc Omega 3 fatty acid formulations
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
WO2009053824A1 (en) 2007-10-23 2009-04-30 Laboratorio Chimico Internazionale S.P.A. Lipoic acid pellet composition
US20110129442A1 (en) 2007-10-23 2011-06-02 Magri Paolo Lipoic acid pellet composition
WO2009095670A1 (en) 2008-01-29 2009-08-06 Ayanda As Soft gel capsules
JP5238954B2 (en) 2008-02-29 2013-07-17 株式会社大一商会 Game machine
WO2010041015A2 (en) 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
US20110268770A1 (en) 2008-10-08 2011-11-03 Probio Asa Chewable gelled emulsions
WO2010041017A2 (en) 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
WO2011128634A2 (en) 2010-04-14 2011-10-20 Probio Asa Over the counter pharmaceutical compositions
US20130274280A1 (en) 2010-04-14 2013-10-17 Ayanda Group As Anti-abuse gelled pharmaceutical compositions
US20130273025A1 (en) 2010-04-14 2013-10-17 Ayanda Group As Oral veterinary pharmaceutical and nutraceutical compositions

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
Applicant submission to European Patent Office, "Request for Examination" and accompanying remarks, in counterpart European Application No. 15172196.6, dated May 27, 2016 (6 pages).
Eurasian Patent Office, Office Action issued in Eurasian Patent Application No. 201290985/28, mailed Jan. 16, 2015.
European Patent Office, "Communication under Rule 71(3)EPC-Intention to grant" and related Annex, issued in counterpart European Application No. 15172196.6, dated Sep. 21, 2016 (34 pages).
European Patent Office, "Communication-Extended European Search Report" and related Annex, issued in counterpart European Application No. 15172196.6, dated Nov. 5, 2015 (7 pages).
European Patent Office, "Communication under Rule 71(3)EPC—Intention to grant" and related Annex, issued in counterpart European Application No. 15172196.6, dated Sep. 21, 2016 (34 pages).
European Patent Office, "Communication—Extended European Search Report" and related Annex, issued in counterpart European Application No. 15172196.6, dated Nov. 5, 2015 (7 pages).
European Patent Office, Acting as the International Search Authority,International Search Report and Written Opinion, PCT International Patent Application No. PCT/GB2011/000560, May 9, 2012.
European Patent Office, Examination, Communication Pursuant to article 94(3) EPC, European Application No. 11 715 601.8-1455, Feb. 11, 2014.
European Patent Office, International Searching Authority, International Search Report, Mar. 21, 2012, European Patent Office, International Patent Application No. PCT/GB2011/000565, 2280 HV Rijswijk, The Netherlands.
European Patent Office/International Search Authority, International Search Report and Written Opinion, PCT/GB2009/0085840, Jul. 19, 2010.
European Patent Office/International Searching Authority-"International Search Report" and "Written Opinion" Issued Apr. 13, 2010 and "International Preliminary Report on Patentability" Issued Apr. 12, 2011; all in PCT/GB2009/002406.
European Patent Office/International Searching Authority-"International Search Report" and "Written Opinion" issued Jul. 19, 2010 and "International Preliminary Report on Patentability" issued Apr. 12, 2011; all in PCT/GB2009/002404.
European Patent Office/International Searching Authority—"International Search Report" and "Written Opinion" Issued Apr. 13, 2010 and "International Preliminary Report on Patentability" Issued Apr. 12, 2011; all in PCT/GB2009/002406.
European Patent Office/International Searching Authority—"International Search Report" and "Written Opinion" issued Jul. 19, 2010 and "International Preliminary Report on Patentability" issued Apr. 12, 2011; all in PCT/GB2009/002404.
Examination Report issued in counterpart European Application No. 09785201.6 on Nov. 29, 2012 by the European Patent Office.
Folador et al., "Fish meals, fish components, and fish protein hydrolysates as potential ingredients in pet foods", Journal of Animal Science 84(10):2752-2765 (2006).
Hellio et al., "Physically and Chemically Crosslinked Gelatin Gels", Macromolecular Symposia 2006, vol. 241, pp. 23-27.
International Searching Authority, International Preliminary Report on Patentability, Oct. 16, 2012, European Patent Office, International Patent Application No. PCT/GB2011/000565, 2280 HV Rijswijk, The Netherlands.
International Searching Authority, International Search Report and the Written Opinion of the International Searching Authority, European Patent Office, 2280 HV Rijswijk, The Netherlands.
James K. Roush et al, Multicenter Veterinary Practice Assessment of the effects of Omega-3 Fatty Acids on Osteoarthritis in Dogs, Journal of the American Veterinary Medical Association, Jan. 1, 2010, 59-66, vol. 236 No. 1, American Veterinary Medical Associaion, Schaumburg, IL, USA.
Japanese Patent Office, Office Action Decision of Rejection issued in Japanese Patent Application No. 2013-504328 on Sep. 8, 2015.
Japanese Patent Office, Office Action issued in Japanese Patent Application No. 2013-504328, mailed Jan. 6, 2015.
Kurt Ingar Draget, co-pending U.S. Appl. No. 13/641,097, 371(c) filing date of Jun. 4, 2013.
MSD Animal Health website, http://www.msd-animal-health.co.uk/Products-Public/Tryplase/Product-datasheet.aspx, Tryplase Capsules, web page is still active, copy was retrieved Jun. 17, 2013.
MSD Animal Health website, http://www.msd-animal-health.co.uk/Products—Public/Tryplase/Product—datasheet.aspx, Tryplase Capsules, web page is still active, copy was retrieved Jun. 17, 2013.
Office Action and Notice of References Cited Issued by the US Patent & Trademark Office on Oct. 9, 2012 and on Jan. 29, 2013 in copending U.S. Appl. No. 13/123,163.
Patent Office of Japan: Office Action Issued Jul. 11, 2013 in counterpart Japanese Application No. 2011-530554.
Pet Prescription website, http://petprescription.co.uk, Canikur Pro Paste, web page is archived and no longer available, Indexed on Sep. 18, 2010.
Rowena Dinham, Patents Act 1977: Search Report under Section 17(5), Intellectual Property Office, Aug. 20, 2010, Patents Directorate, Cardiff Road, Newport, South Wales, UK.
Search Report issued in UK Application No. GB 0818473.1 on Feb. 5, 2009, serving as a priority document to the present application.
Susan K. Raatz et al, Enhanced Absorption of n-3 Fatty Acids from Emulsified Compared with Encapsulated Fish Oil, Journal of the American Dietetic Association, Jun. 2009, 1076-1081, vol. 109 No. 6, Elsevier Inc., Iowa City, IA, USA.
The UK Patent Office, "Search Report" issued in UK Application No. GB0818472.3 on Feb. 6, 2009.
Tore Seternes et al, "Chewable Gelled Emulsions", U.S. Appl. No. 13/123,163, filed Apr. 7, 2011, national phase application of WO2010/0041017.
UK Intellectual Property Office, Patents Act 1977: Search Report under Section 17(5), Intellectual Property Office, Aug. 23, 2010, Patents Directorate, Cardiff Road, Newport, South Wales, UK, Patent Application No. GB1006699.1.
United Kingdom Intellectual Property Office, Patents Act 1977: Search Report under Section 17(5), Aug. 25, 2010, Patents Directorate, Cardiff Road, Newport, South Wales, UK, Application No. GB1006200.8.
United States Patent and Trademark Office, "Notice of Allowance" and related documents issued Aug. 29, 2016 in U.S. Appl. No. 12/162,339.
United States Patent and Trademark Office, "Office Action" and "Notice of References Cited" issued May 18, 2016, and "Office Action" issued Nov. 15, 2016, in U.S. Appl. No. 13/641,084.
United States Patent and Trademark Office, "Office Action" and "Notice of References Cited", issued Dec. 19, 2016 in U.S. Appl. No. 13/641,081.
US Patent and Trademark Office, U.S. Appl. No. 12/162,339, Non-Final Office Actions issued Dec. 4, 2015; Mar. 12, 2014; and Jul. 20, 2011; Final Office Actions issued Dec. 22, 2014 and Feb. 16, 2012; and Restriction Requirement issued Jun. 2, 2011.
US Patent and Trademark Office, U.S. Appl. No. 13/641,081, Non-Final Office Actions issued Mar. 22, 2016 and Jul. 15, 2014; Final Office Action issued May 18, 2015; and Restriction Requirement issued Dec. 6, 2013.
US Patent and Trademark Office, U.S. Appl. No. 13/641,084, Non-Final Office Action issued Jul. 9, 2015; and Restriction Requirement issued Feb. 4, 2015.
Yokoyama et al., "Effects of elcosaepentanoic acid on major coronary events . . . " Lancet 369:1090-1098 (2007).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016359B2 (en) 2022-11-11 2024-06-25 Pharmavite Llc Oil-in-water emulsion gummy composition with water soluble active ingredient(s)

Also Published As

Publication number Publication date
JP5685540B2 (en) 2015-03-18
US10668013B2 (en) 2020-06-02
ES2919148T3 (en) 2022-07-22
EP3311801A3 (en) 2018-07-25
US20170296467A1 (en) 2017-10-19
EP2952176B1 (en) 2017-11-29
CA2742966A1 (en) 2010-04-15
CA3007681A1 (en) 2010-04-15
GB0818473D0 (en) 2008-11-12
EP3311801B1 (en) 2022-06-01
PL3311801T3 (en) 2022-08-29
EP2952176A1 (en) 2015-12-09
US20110268771A1 (en) 2011-11-03
IL212196A0 (en) 2011-06-30
CA2890567A1 (en) 2010-04-15
ES2657276T3 (en) 2018-03-02
JP2012505189A (en) 2012-03-01
CA3007681C (en) 2021-03-16
WO2010041015A3 (en) 2010-09-10
CA2890567C (en) 2018-07-17
WO2010041015A2 (en) 2010-04-15
EP2346490A2 (en) 2011-07-27
US20150037438A1 (en) 2015-02-05
PL2952176T3 (en) 2018-05-30
EP3311801A2 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US10668013B2 (en) Chewable gelled emulsions
US20110268770A1 (en) Chewable gelled emulsions
CN110944641A (en) Gelatin adhesive composition and methods of making and using the same
IE72146B1 (en) Pharmaceutical composition in gel form in a dispensing package
CA2813696A1 (en) Sour gelled emulsions
US20060165795A1 (en) Medicinal compositions comprising a core and a film based on modified cellulose derivatives
CA2833105C (en) Oral pharmaceutical dispersion compositions
US11857557B2 (en) Oral dissolvable film containing vitamin D3
JP6609532B2 (en) Oral pharmaceutical dispersion composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: AYANDA AS, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SETERNES, TORE;DRAGET, KURT INGAR;HAUG, INGVILD JOHANNE;REEL/FRAME:037262/0304

Effective date: 20110624

Owner name: PROBIO ASA, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AYANDA AS;REEL/FRAME:037262/0473

Effective date: 20110630

Owner name: AYANDA GROUP AS, NORWAY

Free format text: CHANGE OF ADDRESS;ASSIGNOR:AYANDA GROUP AS;REEL/FRAME:037266/0374

Effective date: 20121012

Owner name: AYANDA GROUP AS, NORWAY

Free format text: CHANGE OF NAME;ASSIGNOR:PROBIO ASA;REEL/FRAME:037415/0354

Effective date: 20120611

AS Assignment

Owner name: AYANDA GROUP AS, NORWAY

Free format text: CHANGE OF ADDRESS;ASSIGNOR:AYANDA GROUP AS;REEL/FRAME:037550/0837

Effective date: 20160112

AS Assignment

Owner name: VITUX GROUP AS, NORWAY

Free format text: CHANGE OF NAME;ASSIGNOR:AYANDA GROUP AS;REEL/FRAME:041929/0696

Effective date: 20170314

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4